Eden Biodesign and Millipore in partnership to offer pharmaceutical
manufacturing and gene expression technology
1 April 2010
Eden Biodesign Ltd and Millipore Corporation have announced a
partnership that will provide biopharmaceutical companies with access to
a combination of Eden’s cGMP manufacturing and Millipore’s Ubiquitous
Chromatin Opening Elements (UCOE) expression technology.
As part of this agreement, Eden Biodesign will employ Millipore’s
proprietary UCOE expression technology to undertake mammalian cell
line development projects and cGMP production for third-party
clients.
Millipore’s UCOE technology provides major improvements in gene
expression for stably transfected mammalian cells through effects on
the structure of chromatin. Cells developed using Millipore’s UCOE
technology are stable high-expressors, which means it is much easier
and faster for biopharmaceutical manufacturers to identify
high-yielding clones with the productivity and stability required
for biomanufacturing than with many other expression systems.
“We are delighted to work with a recognized industry leader like
Millipore to make this extremely valuable technology available to
our clients around the world,” said Roger Lias, PhD, president of
Eden Biodesign’s North American subsidiary.
“Speed-to-clinic and the ability to rapidly develop highly
productive cell lines that will support economically viable
production through clinical development, process scale-up and
steady-state large scale commercial supply are vitally important
considerations for our clients.”
“Millipore is committed to bringing innovation that solves
critical biopharmaceutical manufacturing business needs. Our
distinctive UCOE technology, with its high expression elements,
revolutionizes the speed by which protein therapeutics can be
produced in mammalian cells,” said Andrew Bulpin, PhD, Vice
President, Upstream Processing for Millipore’s Bioprocess Division.
“We are pleased to collaborate with Eden Biodesign in the complex
mammalian cell development arena and have high expectations for the
ongoing success of this partnership.”